论文信息 - SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications - 字舞流文

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

M. Heuser | F. Thol | A. Ganser | O. Bernard | M. Fontenay | B. Schlegelberger | G. Göhring | O. Kosmider | O. Beyne-Rauzy | F. Dreyfus | S. Botton | F. Damm | A. Guerci-Bresler | A. Tanguy‐Schmidt | A. Stamatoullas-Bastard | S. Kade | P. Löffeld | Olivier A. Bernard | Frederik Damm | A. Ganser | Sofia Kade | Patrick Löffeld

[1] A. Jankowska,et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.

[2] K. Wagner,et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes , 2011, Haematologica.

[3] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[4] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[5] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[6] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] B. Quesnel,et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[8] R. Arceci. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011 .

[9] Michael Heuser,et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.

[10] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[11] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.

[12] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[13] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[14] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[15] M. Jädersten,et al. Myelodysplastic syndromes: biology and treatment , 2009, Journal of internal medicine.

[16] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.